Эффективность и безопасность применения лозартана и его комбинации со спиронолактоном у пациентов с гипертрофической кардиомиопатией

The results of the compare efficacy and safety of long-term therapy with the combination of RAAS blockers блокаторов (ARB and spironolactone) in patients with hypertrophic cardiomyopathy. Inclusion of combined losartan and spironolactone in therapy of HCM patients together with beta-adrenergic blocking agents during a 12-month period hampers progression of diastolic dysfunction and causes myocardial fibrosis. Keywords: hypertrophic cardiomyopathy, diastolic dysfunction, losartan, spironolactone.